Azitra (AZTR) Corporate presentation summary

Foundational technology and platforms

• Utilizes synthetic biology and metagenomics to develop precision dermatology solutions.

• Maintains a proprietary library of ~1,500 microbial strains, primarily Staphylococcus epidermidis.

• Employs AI/ML for discovery of novel microbial-derived proteins and peptides.

• Holds exclusive agreements with leading academic institutions for genetic engineering platforms.

Differentiated approach and competitive advantages

• Focuses on topical delivery of engineered bacteria for disease-modifying, safe, and low-cost treatments.

• Demonstrates superior skin penetration and protein delivery compared to traditional therapies.

• Targets orphan dermatology indications with significant unmet needs.

Pipeline overview and clinical programs

• Pipeline includes ATR-12 (Netherton syndrome), ATR-04 (EGFR inhibitor-associated rash), and ATR-01 (ichthyosis vulgaris).

• ATR-12 is in Phase 1b for Netherton syndrome, with Pediatric Rare Disease Designation and a potential $250M peak sales opportunity.

• ATR-04 is Phase 1/2 ready for EGFR inhibitor-associated rash, targeting a >$1B market.

• ATR-01 is in IND-enabling studies for ichthyosis vulgaris, addressing a population of over 1 million in the US.